ACLY and autoimmune polyendocrinopathy: Notably, in a pregnant woman with primary APS who had severe thrombocytopenia and did not respond conventional therapy, weekly rituximab administration from 12 to 15 weeks of gestation increased platelet count while decreasing aCL titer, resulting in a successful pregnancy without preeclampsia or fetal growth restriction (76).